Ignite Creation Date:
2024-05-06 @ 4:24 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04976634
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2021-07-16
Brief Title:
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors MK-6482-016
Sponsor:
Organization:
Merck Sharp Dohme LLC